Citizens Reiterates ProQR Therapeutics N.V. (PRQR) at Market Outperform Ahead of Phase 1 Readout
Tweet Send to a Friend
Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $8.00 price target on ProQR Therapeutics N.V. (NASDAQ: PRQR).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
